Amicus Therapeutics’s Growth And Success

September 26, 2017

There are businesses today that offer the best in the market at the most affordable cost. This goal is possible only because they put a lot of effort in developing the product they’re selling. With the right product that the company sells, they will guarantee the promise of growth and sustained revenue increase. This achievement is nothing new with Amicus Therapeutics


Amicus Therapeutics: The Brand That Lives Up To The Praise


Amicus Therapeutics is right now the best global biotechnology company that offers the trending but sustainable products that offer the best deals on the market. The company’s leadership in the biopharmaceutical industry also gave it the record of being listed on NASDAQ in 2007 under the trading symbol FOLD.


The success of the company was also because of how the managers of their former venture capitalists who helped handle the business’s assets. Some of these venture capital firms include Radius Ventures, Enterprise Associates, and Canaan Partners. All these contribute to the growth’s famous name and progress that many of the clients vouched for today.


The Numbers


With the company’s total equity reaching $50 million and with 92 employees that work with the enterprise, Amicus Therapeutics finds itself winning in the numbers game ( It might be safe to say that the success of Amicus has something to do with the fact that its headquarters is in Cranbury New Jersey, United States, with the key people leading the company and giving it the leadership it needs.


These key people that provided important help to the company include John Crowley and Bradley Campbel, who are the CEO and the COO respectively (SeekingAlpha).


Corporate Management


Amicus Therapeutics is also successful today because of the strong contribution of Brandon Wustman, who held the post as Director of Exploratory Biology in the operations of the firm. It is also the secret of the company to provide the best treatment and care for rare and particular diseases, especially the ones involving the lysosomal storage disorders of the patients.


With Amicus Therapeutics‘ technology called Chaperone-Advanced Replacement THerapy or CHART, it can provide a platform for the development of enzyme replacement therapies that offer a lot of help to the wellbeing of a patient.

More at GCRoport

Leave a Reply

Your email address will not be published. Required fields are marked *